WO2024105180A1 - Biomarqueurs d'efficacité prédictive pour anticorps anti-sirpa - Google Patents
Biomarqueurs d'efficacité prédictive pour anticorps anti-sirpa Download PDFInfo
- Publication number
- WO2024105180A1 WO2024105180A1 PCT/EP2023/082095 EP2023082095W WO2024105180A1 WO 2024105180 A1 WO2024105180 A1 WO 2024105180A1 EP 2023082095 W EP2023082095 W EP 2023082095W WO 2024105180 A1 WO2024105180 A1 WO 2024105180A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- sirpa
- seq
- patient
- antibody
- Prior art date
Links
- 239000000090 biomarker Substances 0.000 title claims abstract description 67
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 396
- 201000011510 cancer Diseases 0.000 claims abstract description 207
- 238000011282 treatment Methods 0.000 claims abstract description 141
- 210000000066 myeloid cell Anatomy 0.000 claims abstract description 131
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 claims abstract description 78
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 58
- 210000001616 monocyte Anatomy 0.000 claims abstract description 51
- 210000000440 neutrophil Anatomy 0.000 claims abstract description 50
- 210000004981 tumor-associated macrophage Anatomy 0.000 claims abstract description 49
- 238000001565 modulated differential scanning calorimetry Methods 0.000 claims abstract 7
- 101150036449 SIRPA gene Proteins 0.000 claims description 344
- 239000012634 fragment Substances 0.000 claims description 185
- 239000000427 antigen Substances 0.000 claims description 152
- 108091007433 antigens Proteins 0.000 claims description 152
- 102000036639 antigens Human genes 0.000 claims description 152
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 145
- 238000000034 method Methods 0.000 claims description 114
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 101
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 90
- 241000282414 Homo sapiens Species 0.000 claims description 74
- 150000001875 compounds Chemical class 0.000 claims description 56
- 230000014509 gene expression Effects 0.000 claims description 54
- 239000012472 biological sample Substances 0.000 claims description 51
- 102000044459 human CD47 Human genes 0.000 claims description 44
- 210000004027 cell Anatomy 0.000 claims description 42
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 34
- 201000005202 lung cancer Diseases 0.000 claims description 34
- 208000020816 lung neoplasm Diseases 0.000 claims description 34
- 229940124060 PD-1 antagonist Drugs 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 33
- 239000000523 sample Substances 0.000 claims description 32
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 31
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 30
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 30
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 30
- 206010009944 Colon cancer Diseases 0.000 claims description 29
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 29
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 29
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 28
- 206010006187 Breast cancer Diseases 0.000 claims description 24
- 208000026310 Breast neoplasm Diseases 0.000 claims description 24
- 206010033128 Ovarian cancer Diseases 0.000 claims description 24
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 24
- 210000004881 tumor cell Anatomy 0.000 claims description 24
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 23
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 23
- 201000010881 cervical cancer Diseases 0.000 claims description 23
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 21
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 claims description 21
- 230000003993 interaction Effects 0.000 claims description 21
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 19
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 19
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 19
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 19
- 229940123751 PD-L1 antagonist Drugs 0.000 claims description 16
- 230000008901 benefit Effects 0.000 claims description 16
- 238000001574 biopsy Methods 0.000 claims description 16
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 15
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 15
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 13
- 206010038389 Renal cancer Diseases 0.000 claims description 13
- 201000010982 kidney cancer Diseases 0.000 claims description 13
- 201000007270 liver cancer Diseases 0.000 claims description 13
- 208000014018 liver neoplasm Diseases 0.000 claims description 13
- 230000004044 response Effects 0.000 claims description 13
- 239000007787 solid Substances 0.000 claims description 13
- 206010014733 Endometrial cancer Diseases 0.000 claims description 12
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 12
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 12
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 12
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 12
- 238000003364 immunohistochemistry Methods 0.000 claims description 12
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 12
- 201000001441 melanoma Diseases 0.000 claims description 12
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 12
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 12
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 11
- 201000010536 head and neck cancer Diseases 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 10
- 206010046766 uterine cancer Diseases 0.000 claims description 10
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 9
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims description 9
- 208000004091 Parotid Neoplasms Diseases 0.000 claims description 9
- 206010060862 Prostate cancer Diseases 0.000 claims description 9
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 9
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 9
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 9
- 208000037844 advanced solid tumor Diseases 0.000 claims description 9
- 201000009036 biliary tract cancer Diseases 0.000 claims description 9
- 102000048776 human CD274 Human genes 0.000 claims description 9
- 102000048362 human PDCD1 Human genes 0.000 claims description 9
- 201000001219 parotid gland cancer Diseases 0.000 claims description 9
- 238000011284 combination treatment Methods 0.000 claims description 8
- -1 STING agonist Proteins 0.000 claims description 6
- 239000000556 agonist Substances 0.000 claims description 6
- 102000005962 receptors Human genes 0.000 claims description 6
- 108020003175 receptors Proteins 0.000 claims description 6
- 108091008875 B cell receptors Proteins 0.000 claims description 3
- 108010029697 CD40 Ligand Proteins 0.000 claims description 3
- 229940123189 CD40 agonist Drugs 0.000 claims description 3
- 102100032937 CD40 ligand Human genes 0.000 claims description 3
- 238000002965 ELISA Methods 0.000 claims description 3
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims description 3
- 102100034980 ICOS ligand Human genes 0.000 claims description 3
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims description 3
- 238000010240 RT-PCR analysis Methods 0.000 claims description 3
- 229940044665 STING agonist Drugs 0.000 claims description 3
- 238000003491 array Methods 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 3
- 238000002038 chemiluminescence detection Methods 0.000 claims description 3
- 230000002255 enzymatic effect Effects 0.000 claims description 3
- 238000001917 fluorescence detection Methods 0.000 claims description 3
- 238000003018 immunoassay Methods 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 244000309459 oncolytic virus Species 0.000 claims description 3
- 238000003752 polymerase chain reaction Methods 0.000 claims description 3
- 238000000163 radioactive labelling Methods 0.000 claims description 3
- 229940044601 receptor agonist Drugs 0.000 claims description 3
- 239000000018 receptor agonist Substances 0.000 claims description 3
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 20
- 210000002865 immune cell Anatomy 0.000 abstract description 16
- 239000005557 antagonist Substances 0.000 abstract description 12
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 abstract description 11
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 abstract description 8
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 abstract description 2
- 102100022338 Integrin alpha-M Human genes 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 39
- 230000004083 survival effect Effects 0.000 description 32
- 229940124597 therapeutic agent Drugs 0.000 description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 201000010099 disease Diseases 0.000 description 21
- 239000003795 chemical substances by application Substances 0.000 description 20
- 238000002648 combination therapy Methods 0.000 description 20
- 238000009097 single-agent therapy Methods 0.000 description 19
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 14
- 239000012270 PD-1 inhibitor Substances 0.000 description 14
- 239000012668 PD-1-inhibitor Substances 0.000 description 14
- 229940121655 pd-1 inhibitor Drugs 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 12
- 239000012190 activator Substances 0.000 description 11
- 239000003623 enhancer Substances 0.000 description 11
- 210000002540 macrophage Anatomy 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000001959 radiotherapy Methods 0.000 description 8
- 108700028369 Alleles Proteins 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 239000000092 prognostic biomarker Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 6
- 101100454808 Caenorhabditis elegans lgg-2 gene Proteins 0.000 description 6
- 101100217502 Caenorhabditis elegans lgg-3 gene Proteins 0.000 description 6
- 206010061818 Disease progression Diseases 0.000 description 6
- 108091092878 Microsatellite Proteins 0.000 description 6
- 206010057249 Phagocytosis Diseases 0.000 description 6
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 6
- 230000005750 disease progression Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000001747 exhibiting effect Effects 0.000 description 6
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 6
- 230000008782 phagocytosis Effects 0.000 description 6
- 229960003301 nivolumab Drugs 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 229950002916 avelumab Drugs 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 229950009791 durvalumab Drugs 0.000 description 4
- 229940055220 ezabenlimab Drugs 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 229960002621 pembrolizumab Drugs 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- 108010017009 CD11b Antigen Proteins 0.000 description 3
- 102000004354 CD11b Antigen Human genes 0.000 description 3
- 208000007300 Fibrolamellar hepatocellular carcinoma Diseases 0.000 description 3
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 3
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 3
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 101710183617 Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 description 3
- 210000004141 ampulla of vater Anatomy 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229950007213 spartalizumab Drugs 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 2
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 2
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 2
- 101000835928 Homo sapiens Signal-regulatory protein gamma Proteins 0.000 description 2
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 108010030317 Macrophage-1 Antigen Proteins 0.000 description 2
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 102100025795 Signal-regulatory protein gamma Human genes 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229960003852 atezolizumab Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 208000035474 group of disease Diseases 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000001325 log-rank test Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 210000001989 nasopharynx Anatomy 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229950010773 pidilizumab Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 208000037821 progressive disease Diseases 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 229940066453 tecentriq Drugs 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 210000002105 tongue Anatomy 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 239000012130 whole-cell lysate Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100031092 C-C motif chemokine 3 Human genes 0.000 description 1
- 101710155856 C-C motif chemokine 3 Proteins 0.000 description 1
- 102100031102 C-C motif chemokine 4 Human genes 0.000 description 1
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 1
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
- 101100504320 Caenorhabditis elegans mcp-1 gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108010055165 Chemokine CCL4 Proteins 0.000 description 1
- 108010055124 Chemokine CCL7 Proteins 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000393496 Electra Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000709256 Homo sapiens Signal-regulatory protein beta-1 Proteins 0.000 description 1
- 101000709188 Homo sapiens Signal-regulatory protein beta-1 isoform 3 Proteins 0.000 description 1
- 101001087416 Homo sapiens Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 1
- 101000617285 Homo sapiens Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000012220 Member 14 Tumor Necrosis Factor Receptors Human genes 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102100032770 Signal-regulatory protein beta-1 isoform 3 Human genes 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 101710168942 Sphingosine-1-phosphate phosphatase 1 Proteins 0.000 description 1
- 101000930762 Sulfolobus acidocaldarius (strain ATCC 33909 / DSM 639 / JCM 8929 / NBRC 15157 / NCIMB 11770) Signal recognition particle receptor FtsY Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 1
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229950007712 camrelizumab Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007253 cellular alteration Effects 0.000 description 1
- 229940121420 cemiplimab Drugs 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 102000027596 immune receptors Human genes 0.000 description 1
- 108091008915 immune receptors Proteins 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000003622 mature neutrocyte Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 230000017764 negative regulation of mast cell activation Effects 0.000 description 1
- 230000015286 negative regulation of phagocytosis Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 229950007123 tislelizumab Drugs 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'application concerne de manière générale le traitement du cancer chez des patients qui présentent des cellules immunitaires, en particulier des cellules myéloïdes, par exemple des macrophages associés à une tumeur, des monocytes, des cellules dendritiques myéloïdes, des MDSC et/ou une tumeur associant des neutrophiles, qui expriment les marqueurs biologiques CD11b et SIRPα dans le microenvironnement d'une tumeur. Ces patients ont été identifiés comme étant les sujets répondant le mieux à des thérapies qui comprennent l'administration d'un anticorps antagoniste anti-SIRPα.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22306687.9 | 2022-11-16 | ||
| EP22306687 | 2022-11-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2024105180A1 true WO2024105180A1 (fr) | 2024-05-23 |
Family
ID=84370637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2023/082095 WO2024105180A1 (fr) | 2022-11-16 | 2023-11-16 | Biomarqueurs d'efficacité prédictive pour anticorps anti-sirpa |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2024105180A1 (fr) |
Citations (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997048723A2 (fr) | 1996-06-17 | 1997-12-24 | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. Hofgartenstrasse 2 | Nouvelles proteines ptp20, pcp-2, bdp1, clk et sirp, produits et procedes connexes |
| WO2000066159A1 (fr) | 1999-04-28 | 2000-11-09 | Faculteit Der Geneeskunde Van De Vrije Universiteit | Methode d'inhibition du fonctionnement des cellules s'utilisant dans des therapies anti-inflammatoires et anti-tumorales |
| WO2001040307A1 (fr) | 1999-11-30 | 2001-06-07 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Anticorps diriges contre les proteines regulatrices de signal |
| WO2006121168A1 (fr) | 2005-05-09 | 2006-11-16 | Ono Pharmaceutical Co., Ltd. | Anticorps monoclonaux humains pour mort programmee 1 (mp-1) et procedes pour traiter le cancer en utilisant des anticorps anti-mp-1 seuls ou associes a d’autres immunotherapies |
| WO2009131453A1 (fr) | 2008-04-23 | 2009-10-29 | Stichting Sanquin Bloedvoorziening | Compositions et procédés pour renforcer le système immunitaire |
| WO2013056352A1 (fr) | 2011-10-19 | 2013-04-25 | University Health Network | Anticorps et fragments d'anticorps ciblant sirp-alpha et leur utilisation pour le traitement de cancers hématologiques |
| WO2014149477A1 (fr) | 2013-03-15 | 2014-09-25 | The Board Of Trustees Of The Leland Stanford Junior University | Procédés d'obtention de doses thérapeutiquement efficaces d'agents anti-cd47 |
| WO2014186761A2 (fr) | 2013-05-17 | 2014-11-20 | The Board Of Trustes Of The Leland Stanford Junior University | Procédés pour déterminer la réactivité à un agent anti-cd47 |
| WO2014194302A2 (fr) | 2013-05-31 | 2014-12-04 | Sorrento Therapeutics, Inc. | Protéines de liaison à l'antigène qui se lient à pd-1 |
| WO2015138600A2 (fr) | 2014-03-11 | 2015-09-17 | The Board Of Trustees Of The Leland Stanford Junior University | Anticorps anti-sirp-alpha et anticorps bispécifiques de stimulation des macrophages |
| WO2016063233A1 (fr) | 2014-10-24 | 2016-04-28 | Effimune | Procédé et compositions permettant l'induction d'une différenciation des cellules myéloïdes suppressives pour traiter le cancer et les maladies infectieuses |
| WO2016205042A1 (fr) | 2015-06-16 | 2016-12-22 | The Board Of Trustees Of The Leland Stanford Junior University | Anticorps agonistes de sirpα |
| WO2017019846A1 (fr) | 2015-07-30 | 2017-02-02 | Macrogenics, Inc. | Molécules se liant à pd-1 et méthodes d'utilisation correspondantes |
| WO2017025016A1 (fr) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Anticorps anti-pd-1 |
| WO2017040790A1 (fr) | 2015-09-01 | 2017-03-09 | Agenus Inc. | Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci |
| WO2017132825A1 (fr) | 2016-02-02 | 2017-08-10 | 华为技术有限公司 | Procédé de vérification de puissance d'émission, équipement utilisateur et station de base |
| WO2017133540A1 (fr) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Anticorps anti-pd-1 |
| WO2017178653A2 (fr) | 2016-04-14 | 2017-10-19 | Ose Immunotherapeutics | Nouveaux anticorps anti-sirpa et leurs applications thérapeutiques |
| WO2018008470A1 (fr) | 2016-07-05 | 2018-01-11 | 国立大学法人神戸大学 | Agent antitumoral |
| WO2018026600A1 (fr) | 2016-08-03 | 2018-02-08 | The Board Of Trustees Of The Leland Stanford Junior University | L'interruption de l'engagement du récepteur fc sur les macrophages améliore l'efficacité de la thérapie par anticorps anti-sirpalpha |
| WO2018057669A1 (fr) | 2016-09-21 | 2018-03-29 | Alexo Therapeutics Inc. | Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation |
| WO2018107058A1 (fr) | 2016-12-09 | 2018-06-14 | Alector Llc | Anticorps anti-sirp-alpha et leurs procédés d'utilisation |
| WO2018141964A1 (fr) | 2017-02-06 | 2018-08-09 | Orionis Biosciences Nv | Protéines chimériques ciblées et leurs utilisations |
| WO2018160739A1 (fr) | 2017-02-28 | 2018-09-07 | The Board Of Trustees Of The Leland Stanford Junior University | Activité antifibrotique du blocage de cd47 |
| WO2018190719A2 (fr) | 2017-04-13 | 2018-10-18 | Aduro Biotech Holdings, Europe B.V. | Anticorps anti-sirp alpha |
| WO2018210793A2 (fr) | 2017-05-16 | 2018-11-22 | Synthon Biopharmaceuticals B.V. | ANTICORPS ANTI-SIRPα |
| WO2019023347A1 (fr) | 2017-07-26 | 2019-01-31 | Forty Seven, Inc. | Anticorps anti-sirp-alpha et méthodes associées |
| WO2019073080A1 (fr) * | 2017-10-13 | 2019-04-18 | Ose Immunotherapeutics | Anticorps anti-sirpa modifiés et leurs utilisations |
| WO2019183266A1 (fr) | 2018-03-21 | 2019-09-26 | ALX Oncology Inc. | Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation |
| WO2019200462A1 (fr) | 2018-04-16 | 2019-10-24 | Adaerata, Limited Partnership | Méthodes de prévention ou de traitement de cancers positifs pour slamf7 et négatifs pour slamf7 |
| WO2019226973A1 (fr) | 2018-05-25 | 2019-11-28 | Alector Llc | Anticorps anti-sirpa et leurs procédés d'utilisation |
| WO2020006374A2 (fr) | 2018-06-29 | 2020-01-02 | Alector Llc | Anticorps anti-sirp-bêta1 et procédés d'utilisation associés |
| WO2020013170A1 (fr) | 2018-07-10 | 2020-01-16 | 国立大学法人神戸大学 | ANTIBODY ANTI-SIRPα |
| WO2020033646A1 (fr) | 2018-08-08 | 2020-02-13 | Orionis Biosciences, Inc. | PROTÉINES CHIMÈRES CIBLÉES SUR SIRP1α ET LEURS UTILISATIONS |
| WO2020068752A1 (fr) | 2018-09-27 | 2020-04-02 | Celgene Corporation | PROTÉINES DE LIAISON SIRPα ET MÉTHODES D'UTILISATION DE CELLES-CI |
| WO2020099653A1 (fr) | 2018-11-15 | 2020-05-22 | Byondis B.V. | ANTICORPS ANTI-SIRPα HUMANISÉS |
| WO2020102422A1 (fr) | 2018-11-14 | 2020-05-22 | Arch Oncology, Inc. | ANTICORPS SIRPα THÉRAPEUTIQUES |
| WO2020107115A1 (fr) | 2018-11-29 | 2020-06-04 | Trillium Therapeutics Inc. | Biomarqueurs pour une thérapie de blocage de cd47 |
| CN111635458A (zh) | 2020-03-20 | 2020-09-08 | 上海健信生物医药科技有限公司 | 靶向Sirpα的抗体或其抗原结合片段及其制备和应用 |
| WO2020180811A1 (fr) | 2019-03-04 | 2020-09-10 | Qilu Puget Sound Biotherapeutics Corporation | ANTICORPS ANTI-SIRPα |
| CN111995682A (zh) | 2020-08-21 | 2020-11-27 | 博奥信生物技术（南京）有限公司 | 抗人SIRPα单克隆抗体及其用途 |
| CN112010979A (zh) | 2020-08-21 | 2020-12-01 | 博奥信生物技术（南京）有限公司 | 一种抗人SIRPα单克隆抗体及其用途 |
| WO2020247820A1 (fr) | 2019-06-07 | 2020-12-10 | ALX Oncology Inc. | Procédés et réactifs pour réduire les interférences de médicaments se liant au cd47 dans des dosages sérologiques |
| WO2021022044A1 (fr) | 2019-07-31 | 2021-02-04 | Forty Seven, Inc. | Régimes d'appauvrissement pour une thérapie à lymphocytes t ou à cellules nk modifiés |
| WO2021032078A1 (fr) | 2019-08-20 | 2021-02-25 | Elpiscience (Suzhou) Biopharma, Ltd. | Nouveaux anticorps anti-sirpa |
| CN112574310A (zh) | 2020-12-11 | 2021-03-30 | 浙江博锐生物制药有限公司 | 抗SIRPα抗体及其用途 |
| WO2021076908A1 (fr) | 2019-10-18 | 2021-04-22 | Forty Seven, Inc. | Polythérapies pour le traitement de syndromes myélodysplasiques et de la leucémie myéloïde aiguë |
| WO2021129697A1 (fr) | 2019-12-24 | 2021-07-01 | Lanova Medicines Limited Company | ANTICORPS MONOCLONAUX ANTI-SIRPα ET LEURS UTILISATIONS |
| WO2021174127A1 (fr) | 2020-02-28 | 2021-09-02 | Apexigen, Inc. | Anticorps anti-sirpa et méthodes d'utilisation |
| WO2021222746A2 (fr) | 2020-04-30 | 2021-11-04 | Arch Oncology, Inc. | ANTICORPS SIRPα THÉRAPEUTIQUES |
| WO2021226591A1 (fr) | 2020-05-08 | 2021-11-11 | Electra Therapeutics, Inc. | Anticorps dirigés contre sirp alpha, sirp bêta 1, et sirp gamma et leurs utilisations |
| CN113735973A (zh) | 2020-05-28 | 2021-12-03 | 中国科学院微生物研究所 | 一种抗SIRPα抗体及其应用 |
| WO2022254379A1 (fr) | 2021-06-04 | 2022-12-08 | Boehringer Ingelheim International Gmbh | Anticorps anti-sirp-alpha |
-
2023
- 2023-11-16 WO PCT/EP2023/082095 patent/WO2024105180A1/fr unknown
Patent Citations (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997048723A2 (fr) | 1996-06-17 | 1997-12-24 | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. Hofgartenstrasse 2 | Nouvelles proteines ptp20, pcp-2, bdp1, clk et sirp, produits et procedes connexes |
| WO2000066159A1 (fr) | 1999-04-28 | 2000-11-09 | Faculteit Der Geneeskunde Van De Vrije Universiteit | Methode d'inhibition du fonctionnement des cellules s'utilisant dans des therapies anti-inflammatoires et anti-tumorales |
| WO2001040307A1 (fr) | 1999-11-30 | 2001-06-07 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Anticorps diriges contre les proteines regulatrices de signal |
| WO2006121168A1 (fr) | 2005-05-09 | 2006-11-16 | Ono Pharmaceutical Co., Ltd. | Anticorps monoclonaux humains pour mort programmee 1 (mp-1) et procedes pour traiter le cancer en utilisant des anticorps anti-mp-1 seuls ou associes a d’autres immunotherapies |
| WO2009131453A1 (fr) | 2008-04-23 | 2009-10-29 | Stichting Sanquin Bloedvoorziening | Compositions et procédés pour renforcer le système immunitaire |
| WO2013056352A1 (fr) | 2011-10-19 | 2013-04-25 | University Health Network | Anticorps et fragments d'anticorps ciblant sirp-alpha et leur utilisation pour le traitement de cancers hématologiques |
| WO2014149477A1 (fr) | 2013-03-15 | 2014-09-25 | The Board Of Trustees Of The Leland Stanford Junior University | Procédés d'obtention de doses thérapeutiquement efficaces d'agents anti-cd47 |
| WO2014186761A2 (fr) | 2013-05-17 | 2014-11-20 | The Board Of Trustes Of The Leland Stanford Junior University | Procédés pour déterminer la réactivité à un agent anti-cd47 |
| WO2014194302A2 (fr) | 2013-05-31 | 2014-12-04 | Sorrento Therapeutics, Inc. | Protéines de liaison à l'antigène qui se lient à pd-1 |
| WO2015138600A2 (fr) | 2014-03-11 | 2015-09-17 | The Board Of Trustees Of The Leland Stanford Junior University | Anticorps anti-sirp-alpha et anticorps bispécifiques de stimulation des macrophages |
| WO2016063233A1 (fr) | 2014-10-24 | 2016-04-28 | Effimune | Procédé et compositions permettant l'induction d'une différenciation des cellules myéloïdes suppressives pour traiter le cancer et les maladies infectieuses |
| WO2016205042A1 (fr) | 2015-06-16 | 2016-12-22 | The Board Of Trustees Of The Leland Stanford Junior University | Anticorps agonistes de sirpα |
| WO2017019846A1 (fr) | 2015-07-30 | 2017-02-02 | Macrogenics, Inc. | Molécules se liant à pd-1 et méthodes d'utilisation correspondantes |
| WO2017024465A1 (fr) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Anticorps anti-pd-1 |
| WO2017025016A1 (fr) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Anticorps anti-pd-1 |
| WO2017040790A1 (fr) | 2015-09-01 | 2017-03-09 | Agenus Inc. | Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci |
| WO2017132825A1 (fr) | 2016-02-02 | 2017-08-10 | 华为技术有限公司 | Procédé de vérification de puissance d'émission, équipement utilisateur et station de base |
| WO2017133540A1 (fr) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Anticorps anti-pd-1 |
| WO2017178653A2 (fr) | 2016-04-14 | 2017-10-19 | Ose Immunotherapeutics | Nouveaux anticorps anti-sirpa et leurs applications thérapeutiques |
| WO2018008470A1 (fr) | 2016-07-05 | 2018-01-11 | 国立大学法人神戸大学 | Agent antitumoral |
| WO2018026600A1 (fr) | 2016-08-03 | 2018-02-08 | The Board Of Trustees Of The Leland Stanford Junior University | L'interruption de l'engagement du récepteur fc sur les macrophages améliore l'efficacité de la thérapie par anticorps anti-sirpalpha |
| WO2018057669A1 (fr) | 2016-09-21 | 2018-03-29 | Alexo Therapeutics Inc. | Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation |
| WO2018107058A1 (fr) | 2016-12-09 | 2018-06-14 | Alector Llc | Anticorps anti-sirp-alpha et leurs procédés d'utilisation |
| US20190275150A1 (en) * | 2016-12-09 | 2019-09-12 | Alector Llc | Anti-SIRP-Alpha Antibodies and Methods of Use Thereof |
| WO2018141964A1 (fr) | 2017-02-06 | 2018-08-09 | Orionis Biosciences Nv | Protéines chimériques ciblées et leurs utilisations |
| WO2018160739A1 (fr) | 2017-02-28 | 2018-09-07 | The Board Of Trustees Of The Leland Stanford Junior University | Activité antifibrotique du blocage de cd47 |
| WO2018190719A2 (fr) | 2017-04-13 | 2018-10-18 | Aduro Biotech Holdings, Europe B.V. | Anticorps anti-sirp alpha |
| WO2018210793A2 (fr) | 2017-05-16 | 2018-11-22 | Synthon Biopharmaceuticals B.V. | ANTICORPS ANTI-SIRPα |
| WO2019023347A1 (fr) | 2017-07-26 | 2019-01-31 | Forty Seven, Inc. | Anticorps anti-sirp-alpha et méthodes associées |
| WO2019073080A1 (fr) * | 2017-10-13 | 2019-04-18 | Ose Immunotherapeutics | Anticorps anti-sirpa modifiés et leurs utilisations |
| WO2019183266A1 (fr) | 2018-03-21 | 2019-09-26 | ALX Oncology Inc. | Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation |
| WO2019200462A1 (fr) | 2018-04-16 | 2019-10-24 | Adaerata, Limited Partnership | Méthodes de prévention ou de traitement de cancers positifs pour slamf7 et négatifs pour slamf7 |
| WO2019226973A1 (fr) | 2018-05-25 | 2019-11-28 | Alector Llc | Anticorps anti-sirpa et leurs procédés d'utilisation |
| WO2020006374A2 (fr) | 2018-06-29 | 2020-01-02 | Alector Llc | Anticorps anti-sirp-bêta1 et procédés d'utilisation associés |
| WO2020013170A1 (fr) | 2018-07-10 | 2020-01-16 | 国立大学法人神戸大学 | ANTIBODY ANTI-SIRPα |
| WO2020033646A1 (fr) | 2018-08-08 | 2020-02-13 | Orionis Biosciences, Inc. | PROTÉINES CHIMÈRES CIBLÉES SUR SIRP1α ET LEURS UTILISATIONS |
| WO2020068752A1 (fr) | 2018-09-27 | 2020-04-02 | Celgene Corporation | PROTÉINES DE LIAISON SIRPα ET MÉTHODES D'UTILISATION DE CELLES-CI |
| WO2020102422A1 (fr) | 2018-11-14 | 2020-05-22 | Arch Oncology, Inc. | ANTICORPS SIRPα THÉRAPEUTIQUES |
| WO2020099653A1 (fr) | 2018-11-15 | 2020-05-22 | Byondis B.V. | ANTICORPS ANTI-SIRPα HUMANISÉS |
| WO2020107115A1 (fr) | 2018-11-29 | 2020-06-04 | Trillium Therapeutics Inc. | Biomarqueurs pour une thérapie de blocage de cd47 |
| WO2020180811A1 (fr) | 2019-03-04 | 2020-09-10 | Qilu Puget Sound Biotherapeutics Corporation | ANTICORPS ANTI-SIRPα |
| WO2020247820A1 (fr) | 2019-06-07 | 2020-12-10 | ALX Oncology Inc. | Procédés et réactifs pour réduire les interférences de médicaments se liant au cd47 dans des dosages sérologiques |
| WO2021022044A1 (fr) | 2019-07-31 | 2021-02-04 | Forty Seven, Inc. | Régimes d'appauvrissement pour une thérapie à lymphocytes t ou à cellules nk modifiés |
| US20210347908A1 (en) | 2019-08-20 | 2021-11-11 | Elpiscience (Suzhou) Biopharma, Ltd. | Novel anti-sirpa antibodies |
| WO2021032078A1 (fr) | 2019-08-20 | 2021-02-25 | Elpiscience (Suzhou) Biopharma, Ltd. | Nouveaux anticorps anti-sirpa |
| WO2021076908A1 (fr) | 2019-10-18 | 2021-04-22 | Forty Seven, Inc. | Polythérapies pour le traitement de syndromes myélodysplasiques et de la leucémie myéloïde aiguë |
| WO2021129697A1 (fr) | 2019-12-24 | 2021-07-01 | Lanova Medicines Limited Company | ANTICORPS MONOCLONAUX ANTI-SIRPα ET LEURS UTILISATIONS |
| WO2021174127A1 (fr) | 2020-02-28 | 2021-09-02 | Apexigen, Inc. | Anticorps anti-sirpa et méthodes d'utilisation |
| WO2021185273A1 (fr) | 2020-03-20 | 2021-09-23 | 上海健信生物医药科技有限公司 | ANTICORPS CIBLANT SIRPα OU FRAGMENT DE LIAISON À L'ANTIGÈNE DE CELUI-CI, PRÉPARATION ET UTILISATION ASSOCIÉES |
| CN111635458A (zh) | 2020-03-20 | 2020-09-08 | 上海健信生物医药科技有限公司 | 靶向Sirpα的抗体或其抗原结合片段及其制备和应用 |
| WO2021222746A2 (fr) | 2020-04-30 | 2021-11-04 | Arch Oncology, Inc. | ANTICORPS SIRPα THÉRAPEUTIQUES |
| WO2021226591A1 (fr) | 2020-05-08 | 2021-11-11 | Electra Therapeutics, Inc. | Anticorps dirigés contre sirp alpha, sirp bêta 1, et sirp gamma et leurs utilisations |
| WO2021226576A1 (fr) | 2020-05-08 | 2021-11-11 | Electra Therapeutics, Inc. | Anticorps anti sirp alpha et anti sirp bêta 1 humanisés et leurs utilisations |
| CN113735973A (zh) | 2020-05-28 | 2021-12-03 | 中国科学院微生物研究所 | 一种抗SIRPα抗体及其应用 |
| CN112010979A (zh) | 2020-08-21 | 2020-12-01 | 博奥信生物技术（南京）有限公司 | 一种抗人SIRPα单克隆抗体及其用途 |
| CN111995682A (zh) | 2020-08-21 | 2020-11-27 | 博奥信生物技术（南京）有限公司 | 抗人SIRPα单克隆抗体及其用途 |
| CN112574310A (zh) | 2020-12-11 | 2021-03-30 | 浙江博锐生物制药有限公司 | 抗SIRPα抗体及其用途 |
| WO2022254379A1 (fr) | 2021-06-04 | 2022-12-08 | Boehringer Ingelheim International Gmbh | Anticorps anti-sirp-alpha |
Non-Patent Citations (14)
| Title |
|---|
| "UniProt", Database accession no. P11215 |
| "Uniprot", Database accession no. P78324 |
| ARNOUK SANA ET AL: "Imaging and therapeutic targeting of the tumor immune microenvironment with biologics", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM , NL, vol. 184, 26 March 2022 (2022-03-26), XP087025783, ISSN: 0169-409X, [retrieved on 20220326], DOI: 10.1016/J.ADDR.2022.114239 * |
| BARCLAY, A.N.BROWN, M.H., NAT REV IMMUNOL, vol. 6, 2006, pages 457 - 64 |
| CHAMPIAT S ET AL: "Predictive response biomarkers from Phase I clinical trial of a SIRPalpha inhibitor BI765063, stand-alone and in combination with ezabenlimab, a PD1 inhibitor, in patients with advanced solid tumors | Cancer Research | American Association for Cancer Research", CANCER RESEARCH, 1 April 2023 (2023-04-01), POSTER PRESENTATIONS - PROFFERED ABSTRACTS| APRIL 04 2023 Abstract 2129:, XP093124511, Retrieved from the Internet <URL:https://aacrjournals.org/cancerres/article/83/7_Supplement/2129/724367/Abstract-2129-Predictive-response-biomarkers-from> [retrieved on 20240126] * |
| DIZMAN NAZLI ET AL: "Cancer Therapy Targeting CD47/SIRP[alpha]", CANCERS, 11 December 2021 (2021-12-11), pages 1 - 17, XP093034401, DOI: 10.3390/cancers13246229 * |
| GAUTTIER V ET AL: "Supplemental data", 19 October 2020 (2020-10-19), pages 1 - 28, XP093035269, Retrieved from the Internet <URL:https://www.jci.org/articles/view/135528/sd/1> [retrieved on 20230328] * |
| GAUTTIER VANESSA ET AL, vol. 130, no. 11, 2 November 2020 (2020-11-02), GB, pages 6109 - 6123, XP055832928, ISSN: 0021-9738, Retrieved from the Internet <URL:https://ose-immuno.com/wp-content/uploads/2020/10/SIRPa_JCI-2020.pdf> DOI: 10.1172/JCI135528 * |
| HUBERT M ET AL: "IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer", SCIENCE IMMUNOLOGY, AAAS, US, vol. 5, no. 46, 17 April 2020 (2020-04-17), pages eaav3942 - 1, XP009523096, ISSN: 2470-9468, DOI: 10.1126/SCIIMMUNOL.AAV3942 * |
| KALATHIL SURESH GOPI ET AL: "Importance of myeloid derived suppressor cells in cancer from a biomarker perspective", CELLULAR IMMUNOLOGY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 361, 31 December 2020 (2020-12-31), XP086484911, ISSN: 0008-8749, [retrieved on 20201231], DOI: 10.1016/J.CELLIMM.2020.104280 * |
| MAUTE R. ET AL: "CD47-SIRP[alpha]-targeted therapeutics: status and prospects", IOTECH, vol. 13, 1 March 2022 (2022-03-01), pages 100070, XP093028949, DOI: 10.1016/j.iotech.2022.100070 * |
| SHULTZ, L.D. ET AL., J IMMUNOL, vol. 154, 1995, pages 180 - 91 |
| SI-YANG LIU ET AL., J. HEMATOL. ONCOL., vol. 10, 2017, pages 136 |
| TADAHIKO YANAGITA ET AL: "Anti-SIRP? antibodies as a potential new tool for cancer immunotherapy", vol. 2, no. 1, 12 January 2017 (2017-01-12), pages 1 - 15, XP055421877, ISSN: 2379-3708, Retrieved from the Internet <URL:https://insight.jci.org/articles/view/89140> DOI: 10.1172/jci.insight.89140 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11579142B2 (en) | Dosage regimen for administering a CD19xCD3 bispecific antibody to patients at risk for potential adverse effects | |
| US11807686B2 (en) | Treatment of LAG-3 positive tumors | |
| JP7077226B2 (ja) | Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療 | |
| JP6840127B2 (ja) | がんの治療における抗ｐｄ−１抗体および抗ｍ−ｃｓｆ抗体の併用 | |
| US10983128B2 (en) | CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy | |
| Ma et al. | B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy | |
| JP7474827B2 (ja) | 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置 | |
| TW201620547A (zh) | Ｐｄ－ｌ１陰性腫瘤之組合療法 | |
| US11220543B2 (en) | Antibody binding specifically to CD66c and use thereof | |
| CN112703012A (zh) | 治疗癌症的方法 | |
| KR102195055B1 (ko) | 체크포인트 저해제와 조합된 종양용해 바이러스에 의한 암 요법 | |
| CA3117016A1 (fr) | Polytherapie pour melanome | |
| WO2020211804A1 (fr) | Utilisation d'anticorps anti-pd-1 dans la préparation d'un médicament pour le traitement de tumeurs solides | |
| CN113631230A (zh) | 用于癌症治疗的脑信号蛋白-4d拮抗剂 | |
| WO2024105180A1 (fr) | Biomarqueurs d'efficacité prédictive pour anticorps anti-sirpa | |
| JP2023510075A (ja) | ヒト化抗ｃａ ｉｘ抗体、およびその使用方法 | |
| US20220229059A1 (en) | Tumor cell-derived exosomes and their applications |